The Corporate Advisory Council is a smaller, representative group of the corporate membership-at-large, with an appropriate mix from the corporate membership base. Seats on the council should be held by high-level decision makers within the corporation. The council must be equally balanced between large and small corporations and represent a broad cross section of the Industry.
Through a synergistic relationship between ASTRO and its corporate members, the Corporate Advisory Council will focus on issues and initiatives of mutual concern in radiation oncology to increase awareness of radiation therapy and advance the science and practice of cancer treatment and patient care.
To develop meaningful opportunities for providing and sharing advice and input on areas of mutual concern in radiation oncology. To have greater involvement with and support from the corporate sector in ASTRO activities.
(Adopted by the Board of Directors June 2002)
In the event that the CAC election results do not meet the stated criteria, the Corporate Working Group reserves the right to recommend additional seats (not to exceed three) to achieve the proper balance and representation. Final approval of all seats rests with the Board of Directors.
Nominations for seats can come from any corporate member. To meet the objective of balance on the council, there will be three distinct categories based on size (sales volume in radiation oncology). Each category will have four seats. An annual election in the fall of each year will be held and each corporate member will be entitled to vote for up to three representatives in each category. The ballot will contain all nominees. Following the election, the Corporate Relations Committee will submit the results to the ASTRO Board of Directors for final approval.
Candidates for council seats must meet the following criteria:
There will be no fee for a council seat aside from corporate member dues.
Advisory Council members will have staggered terms with option to run for re-election. Corporation holds seat, not the individual (if seat is vacated by a representative, corporation must reappoint at same level or higher or opt out of seat).
Accuray - Andrew DeLaO
AstraZeneca - Susan Galbraith, PhD
Blue Earth Diagnostics - Terri Wilson
CIVCO Radiotherapy - Nat Geissel
Elekta - Robert Thomas
IBA - Frederic Genin
LAP Laser - Trent van Arkel
Nanobiotix - Laurent Levy, PhD
Standard Imaging Inc. - Eric DeWerd
Sun Nuclear Corporation - Jeff Simon
Varian Medical Systems - Chris Toth
ViewRay Inc. - Shar Matin
Xstrahl - Adrian Treverton